3QRJ

The crystal structure of human abl1 kinase domain T315I mutant in complex with DCC-2036


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.82 Å
  • R-Value Free: 0.286 
  • R-Value Work: 0.229 
  • R-Value Observed: 0.232 

Starting Model: other
View more details

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.3 of the entry. See complete history


Literature

Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036.

Chan, W.W.Wise, S.C.Kaufman, M.D.Ahn, Y.M.Ensinger, C.L.Haack, T.Hood, M.M.Jones, J.Lord, J.W.Lu, W.P.Miller, D.Patt, W.C.Smith, B.D.Petillo, P.A.Rutkoski, T.J.Telikepalli, H.Vogeti, L.Yao, T.Chun, L.Clark, R.Evangelista, P.Gavrilescu, L.C.Lazarides, K.Zaleskas, V.M.Stewart, L.J.Van Etten, R.A.Flynn, D.L.

(2011) Cancer Cell 19: 556-568

  • DOI: https://doi.org/10.1016/j.ccr.2011.03.003
  • Primary Citation of Related Structures:  
    3QRI, 3QRJ, 3QRK

  • PubMed Abstract: 

    Acquired resistance to ABL1 tyrosine kinase inhibitors (TKIs) through ABL1 kinase domain mutations, particularly the gatekeeper mutant T315I, is a significant problem for patients with chronic myeloid leukemia (CML). Using structure-based drug design, we developed compounds that bind to residues (Arg386/Glu282) ABL1 uses to switch between inactive and active conformations. The lead "switch-control" inhibitor, DCC-2036, potently inhibits both unphosphorylated and phosphorylated ABL1 by inducing a type II inactive conformation, and retains efficacy against the majority of clinically relevant CML-resistance mutants, including T315I. DCC-2036 inhibits BCR-ABL1(T315I)-expressing cell lines, prolongs survival in mouse models of T315I mutant CML and B-lymphoblastic leukemia, and inhibits primary patient leukemia cells expressing T315I in vitro and in vivo, supporting its clinical development in TKI-resistant Ph(+) leukemia.


  • Organizational Affiliation

    Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA 02111, USA.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Tyrosine-protein kinase ABL1
A, B
277Homo sapiensMutation(s): 1 
Gene Names: ABL1ABLJTK7
EC: 2.7.10.2
UniProt & NIH Common Fund Data Resources
Find proteins for P00519 (Homo sapiens)
Explore P00519 
Go to UniProtKB:  P00519
PHAROS:  P00519
GTEx:  ENSG00000097007 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP00519
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
919
Query on 919

Download Ideal Coordinates CCD File 
C [auth A],
D [auth B]
4-[4-({[3-tert-butyl-1-(quinolin-6-yl)-1H-pyrazol-5-yl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide
C30 H28 F N7 O3
WVXNSAVVKYZVOE-UHFFFAOYSA-N
Binding Affinity Annotations 
IDSourceBinding Affinity
919 BindingDB:  3QRJ Kd: 7.2 (nM) from 1 assay(s)
IC50: min: 0.75, max: 5 (nM) from 3 assay(s)
PDBBind:  3QRJ IC50: 4 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.82 Å
  • R-Value Free: 0.286 
  • R-Value Work: 0.229 
  • R-Value Observed: 0.232 
  • Space Group: P 1 21 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 55.261α = 90
b = 59.435β = 109.55
c = 76.285γ = 90
Software Package:
Software NamePurpose
BOSdata collection
MOLREPphasing
REFMACrefinement
HKL-2000data reduction
HKL-2000data scaling

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

Revision History  (Full details and data files)

  • Version 1.0: 2011-06-01
    Type: Initial release
  • Version 1.1: 2011-07-13
    Changes: Version format compliance
  • Version 1.2: 2024-02-21
    Changes: Data collection, Database references, Derived calculations
  • Version 1.3: 2024-04-03
    Changes: Refinement description